alogliptin benzoate 850649-62-6

Details:

Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone. In April 2016, the U.S. FDA added a warning about increased risk of heart failure.

Basic Info

Packing: 25kg/drum.
Shipping: By sea or by air.
Payment: T/T,,money gram

Hebei Mojin Biological Technology Co., Ltd. is specialize in the production of chemical raw materials and reagents,located in Shijiazhuang, Hebei Province. In recent decades, under the efforts of all staff, in Shandong, Henan, Guangdong and many other places have our cooperation factories.We have strict quality control for every process to ensure that we provide customers with quality products and establish long-term cooperative relationship with them. So far, Mojin has business with more than 50 countries in the world,the most of companies who bought tons of products come from Europe and North America.Our enterprise purpose is: based on the domestic market, increase investment in research and development, manufacturing quality products, scientific environmental protection and sustainable development road; Expand the international market, serve the society sincerely, and become a modern, ecological, scientific and technological world enterprise.